NEW YORK (GenomeWeb) – Leerink today initiated coverage of Danaher with an Outperform rating and a $93 price target on the firm's shares. 

"We believe the forthcoming company separation allows for a sharpened focus and expanded capital deployment opportunities," analyst Dan Leonard said in a report, adding that he also sees a margin expansion opportunity. All of those factors combined should drive Danaher's stock to outperform the S&P, he said. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.